Volume 42 Issue 2
Apr.  2021
Turn off MathJax
Article Contents
LIN Xiaojun, CHEN Qin, DUAN Wenhua, ZHU Qin, HU Min. Clinical study of intermittent use of 1% atropine on retardation of myopia progression in Chinese school children[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 177-180. doi: 10.16835/j.cnki.1000-9817.2021.02.005
Citation: LIN Xiaojun, CHEN Qin, DUAN Wenhua, ZHU Qin, HU Min. Clinical study of intermittent use of 1% atropine on retardation of myopia progression in Chinese school children[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 177-180. doi: 10.16835/j.cnki.1000-9817.2021.02.005

Clinical study of intermittent use of 1% atropine on retardation of myopia progression in Chinese school children

doi: 10.16835/j.cnki.1000-9817.2021.02.005
  • Received Date: 2020-09-14
  • Rev Recd Date: 2020-12-18
  • Available Online: 2021-04-06
  • Publish Date: 2021-02-25
  •   Objective  To evaluate the long-term ef efficacy and safety of topical 1% atropine for retarding pregressive myopia.  Methods  A randomized controlled study evaluating atropine and placebo in 570 Chinese children aged 8~14 years recruited from pediatric ophthalmology in Yunnan Provincial the Second People's Hospital during Jan. 2015 to Dec. 2019. In experimental group, patients received drops every two weeks for 24 months, then every three weeks for 12 months, followed by no drops for 12 months. In control group, all children wear single focus frame glasses. Spherical equivalent, axial length, intraocular pressure and atropine-related side effects were examined at 6, 12, 24, 36 and 48 months for all children.  Results  At the end of stage Ⅰ, the myopia progression in the atropine treatment group (-0.27±0.81)D was significantly lower than that in the control group (-1.29±0.13)D, and the increase of axial length in the atropine group (0.11±0.13)mm was also significantly lower than that in the control group (0.41±0.19)mm (P < 0.05). At the end of stage Ⅱ, the average myopia progression in the atropine treatment group (-0.31±0.28)D was significantly lower than that in the control group (-0.80±0.66)D (P < 0.01). Similarly, the axial growth of the experimental group (0.14±0.09)mm was significantly lower than that of the control group (0.39±0.14)mm (P < 0.01). After the withdrawal of atropine eye drops (stage Ⅲ), there was no significant refractive regression in the experimental group. During the whole follow-up period, no serious adverse events related to atropine were found.  Conclusion  Local intermittent use of 1% atropine eye drops and the gradual reduction of atropine eye drops can ensure the effectiveness in the treatment of myopia, reducing the side effects of atropine, avoiding refractive regression after drug withdrawal, and improving children's compliance at the same time.
  • loading
  • [1]
    LI Y, LIU J, QI P. The increasing prevalence of myopia in junior high school students in the Haidian District of Beijing, China: a 10-year population-based survey[J]. BMC Ophthalmol, 2017, 17(1): 88. doi: 10.1186/s12886-017-0483-6/open-peer-review
    [2]
    XIANG F, HE M, ZENG Y, et al. Increases in the prevalence of reduced visual acuity and myopia in Chinese children in Guangzhou over the past 20 years[J]. Eye(Lond), 2013, 27(12): 1353-1358. http://www.ncbi.nlm.nih.gov/pubmed/24008929
    [3]
    CHEN M, WU A, ZHANG L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey[J]. BMC Ophthalmol, 2018, 18(1): 159. doi: 10.1186/s12886-018-0829-8
    [4]
    RADA J A, SHELTON S, NORTON T T. The sclera and myopia[J]. Exp Eye Res, 2006, 82: 185-200. DOI: 10.1016/j.exer.2005.08.009.
    [5]
    SAW S M, GAZZARD G, SHIH-YEN E C, et al. Myopia and associated pathological complications[J]. Ophthal Physiol Opt, 2005, 25: 381-391. DOI: 10.1111/j.1475-1313.2005.00298.x.
    [6]
    SAW S M. How blinding is pathological myopia?[J]. Br J Ophthalmol, 2006, 90: 525-526. DOI: 10.1136/bjo.2005.087999.
    [7]
    TANO Y. Pathologic myopia: where are we now?[J]. Am J Ophthalmol, 2002, 134: 645-660. DOI: 10.1016/s0002-9394(02)01883-4.
    [8]
    LIANG C L, YEN E, SU J Y, et al. Impact of family history of high myopia on level and onset of myopia[J]. Invest Ophthalmol Vis Sci, 2004, 45: 3446-3452. DOI: 10.1167/iovs.03-1058.
    [9]
    THORN F, GWIAZDA J, HELD R. Myopia progression is specified by a double exponential growth function[J]. Optom Vis Sci, 2005, 82: 286-297. DOI: 10.1097/01.opx.0000159370.66540.34.
    [10]
    LAM C S, EDWARDS M, MILLODOT M, et al. A 2-year longitudinal study of myopia progression and optical component changes among HongKong schoolchildren[J]. Optom Vis Sci, 1999, 76: 370-380. DOI: 10.1097/00006324-199906000-00016.
    [11]
    CHUA S Y, IKRAM M K, TAN C S, et al. Relative contribution of risk factors for early-onset myopia in young asian children[J]. Invest Ophthalmol Vis Sci, 2015, 56: 8101-8107. DOI: 10.1167/iovs.15-16577.
    [12]
    SHIH K C, CHAN T C, NG A L, et al. Use of atropine for prevention of childhood myopia progression in clinical practice[J]. Eye Contact Lens, 2016, 42: 16-23. DOI: 10.1097/ICL.0000000000000189.
    [13]
    TIDEMAN J W L, POLLING J R, VINGERLING J R, et al. Axial length growth and the risk of developing myopia in European children[J]. Acta Ophthalmol, 2018, 96: 301-309. DOI: 10.1111/aos.13603.
    [14]
    GWIAZDA J, HYMAN L, HUSSEIN M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children[J]. Invest Ophthalmol Vis Sci, 2003, 44: 1492-1500. DOI: 10.1167/iovs.02-0816.
    [15]
    HASEBE S, OHTSUKI H, NONAKA T, et al. Effect of progressive addition lenses on myopia progression in Japanese children: a prospective, randomized, double-masked, crossover trial[J]. Invest Ophthalmol Vis Sci, 2008, 49: 2781-2789. DOI: 10.1167/iovs.07-0385.
    [16]
    BERNTSEN D A, SINNOTT L T, MUTTI D O, et al. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation[J]. Invest Ophthalmol Vis Sci, 2012, 53: 640-649. DOI: 10.1167/iovs.11-7769.
    [17]
    WALLINE J J, LINDSLEY K, VEDULA S S, et al. Interventions to slow progression of myopia in children[J]. Cochrane Database Syst Rev, 2011: CD004916. DOI: 10.1002/14651858.CD004916.pub3.
    [18]
    CHO P, CHEUNG S W. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial[J]. Invest Ophthalmol Vis Sci, 2012, 53: 7077-7085. DOI: 10.1167/iovs.12-10565.
    [19]
    SUN Y, XU F, ZHANG T, et al. Orthokeratology to control myopia progression: a meta-analysis[J]. PLoS One, 2015, 10: e0124535. DOI: 10.1371/journal.pone.0124535.
    [20]
    KANG P, MCALINDEN C, WILDSOET C F. Effects of multifocal soft contact lenses used to slow myopia progression on quality of vision in young adults[J]. Acta Ophthalmol, 2017, 95: e43-e53. DOI: 10.1111/aos.13173.
    [21]
    XIONG S, SANKARIDURG P, NADUVILATH T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review[J]. Acta Ophthalmol, 2017, 95: 551-566. DOI: 10.1111/aos.13403.
    [22]
    SAW S M. A synopsis of the prevalence rates and environmental risk factors for myopia[J]. Clin Exp Optom, 2003, 86: 289-294. DOI: 10.1111/j.1444-0938.2003.tb03124.x.
    [23]
    SHIH Y F, CHEN C H, CHOU A C, et al. Effects of different concentrations of atropine on controlling myopia in myopic children[J]. J Ocul Pharmacol Ther, 1999, 15: 85-90. DOI: 10.1089/jop.1999.15.85.
    [24]
    GWIAZDA J. Treatment options for myopia[J]. Optom Vis Sci, 2009, 86: 624-628. DOI: 10.1097/OPX.0b013e3181a6a225.
    [25]
    MCBRIEN N A, STELL W K, CARR B. How does atropine exert its anti-myopia effects?[J]. Ophthal Physiol Opt, 2013, 33: 373-378. DOI: 10.1111/opo.12052.
    [26]
    CHUA W H, BALAKRISHNAN V, CHAN Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 113: 2285-2291. DOI: 10.1016/j.ophtha.2006.05.062.
    [27]
    CHIA A, CHUA W H, CHEUNG Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses(Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119: 347-354. DOI: 10.1016/j.ophtha.2011.07.031.
    [28]
    CHIA A, CHUA W H, WEN L, et al. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%[J]. Am J Ophthalmol, 2014, 157: 451-457. DOI: 10.1016/j.ajo.2013.09.020.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Article Metrics

    Article views (633) PDF downloads(179) Cited by()
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return